Barbara Klughammer

4.3k total citations · 2 hit papers
51 papers, 3.2k citations indexed

About

Barbara Klughammer is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Barbara Klughammer has authored 51 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Pulmonary and Respiratory Medicine, 32 papers in Oncology and 15 papers in Molecular Biology. Recurrent topics in Barbara Klughammer's work include Lung Cancer Treatments and Mutations (31 papers), Lung Cancer Research Studies (17 papers) and Colorectal Cancer Treatments and Studies (12 papers). Barbara Klughammer is often cited by papers focused on Lung Cancer Treatments and Mutations (31 papers), Lung Cancer Research Studies (17 papers) and Colorectal Cancer Treatments and Studies (12 papers). Barbara Klughammer collaborates with scholars based in Switzerland, Germany and Spain. Barbara Klughammer's co-authors include Tudor–Eliade Ciuleanu, Saulius Cicėnas, Emilio Esteban, Lilia Stelmakh, Federico Cappuzzo, Gaëlle Klingelschmitt, Wolfram Brugger, Dieter Sültemeyer, Murray R. Badger and G. Dean Price and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Barbara Klughammer

49 papers receiving 3.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study

2010 917 citations Federico Cappuzzo, Tudor–Eliade Ciuleanu et al. The Lancet Oncology profile →
Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy

2015 367 citations Tony Mok, Yi‐Long Wu et al. Clinical Cancer Research profile →

Peers

Countries citing papers authored by Barbara Klughammer

Since Specialization

Citations

This map shows the geographic impact of Barbara Klughammer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Barbara Klughammer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Barbara Klughammer more than expected).

Fields of papers citing papers by Barbara Klughammer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Barbara Klughammer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Barbara Klughammer. The network helps show where Barbara Klughammer may publish in the future.

Co-authorship network of co-authors of Barbara Klughammer

This figure shows the co-authorship network connecting the top 25 collaborators of Barbara Klughammer. A scholar is included among the top collaborators of Barbara Klughammer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Barbara Klughammer. Barbara Klughammer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	P805 Selnoflast, a potent NLRP3 inhibitor - results from a phase 1b experimental medicine study in patients with Ulcerative Colitis 2023 ·Journal of Crohn s and Colitis ·Barbara Klughammer, Luca Piali, (unknown), S. Nagel, (unknown), Christoph Jochum, Stanislav Ignatenko, (unknown), Sabrina Danilin, (unknown), (unknown), Petar Šćepanović, Sylvie Retout, (unknown), (unknown), (unknown), (unknown), Andreas D. Christ	4
2	A randomized, double‐blind phase 1b study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of the NLRP3 inhibitor selnoflast in patients with moderate to severe active ulcerative colitis 2023 ·Clinical and Translational Medicine ·Barbara Klughammer, Luca Piali, (unknown), (unknown), (unknown), Christoph Jochum, Stanislav Ignatenko, (unknown), Sabrina Danilin, (unknown), (unknown), Petar Šćepanović, Jitao David Zhang, (unknown), (unknown), Andreas D. Christ	33
3	Characterizing C5 Inhibition with the SMART-Ig Anti-hC5 Antibody Crovalimab in PNH Patients Using Free Available Paratopes 2019 ·Blood ·Alexandre Sostelly, Antoine Soubret, Christoph Bucher, (unknown), (unknown), Gregor Jordan, Barbara Klughammer, Andreas Dieckmann, Taku Fukuzawa, (unknown), (unknown), Sung‐Soo Yoon, Jens Panse, Jun‐ichi Nishimura, Alexander Röth, Zsolt Nagy, Régis Peffault de Latour	2
4	Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non–Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR Mutations 2016 ·Journal of Thoracic Oncology ·Barbara Klughammer, Wolfram Brugger, Federico Cappuzzo, Tudor–Eliade Ciuleanu, Tony Mok, Martin Reck, Eng Huat Tan, Paul Delmar, Gaëlle Klingelschmitt, (unknown), Olivia Spleiss, Lin Wu, David S. Shames	78
5	Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy breakdown → 2015 ·Clinical Cancer Research ·Tony Mok, Yi‐Long Wu, Jin Soo Lee, Chong‐Jen Yu, Virote Sriuranpong, Jennifer Sandoval-Tan, Guia Ladrera, Sumitra Thongprasert, Vichien Srimuninnimit, Meilin Liao, Yunzhong Zhu, Caicun Zhou, Fatima Fuerte, Benjamin Margono, Wei Wen, Julie Tsai, Matt Truman, Barbara Klughammer, David S. Shames, Lin Wu	367
6	PTPRF Expression as a Potential Prognostic/Predictive Marker for Treatment with Erlotinib in Non-Small-Cell Lung Cancer 2015 ·Journal of Thoracic Oncology ·Denis Soulières, Fred R. Hirsch, Frances A. Shepherd, Walter Bordogna, Paul Delmar, David S. Shames, Barbara Klughammer	18
7	Phase II, randomized, biomarker identification trial (MARK) for erlotinib in patients with advanced pancreatic carcinoma 2014 ·Annals of Oncology ·David Propper, Ірина Давиденко, John Bridgewater, Limas Kupčinskas, A. Fittipaldo, Carina Hillenbach, Barbara Klughammer, Michel Ducreux	25
8	Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study 2014 ·British Journal of Cancer ·Eric Van Cutsem, Li Cp, Elżbieta Nowara, Giuseppe Aprile, Malcolm J. Moore, (unknown), J-L. van Laethem, Chiun Hsu, Chee Kian Tham, Salomon M. Stemmer, Rainer W. Lipp, Ali Zeaiter, A. Fittipaldo, (unknown), Barbara Klughammer, Xue Meng, Tudor–Eliade Ciuleanu	35
9	Clinical Validation of a PCR Assay for the Detection of EGFR Mutations in Non–Small-Cell Lung Cancer: Retrospective Testing of Specimens from the EURTAC Trial 2014 ·PLoS ONE ·Susana Benlloch, María Luisa Botero, (unknown), Clara Mayo, Ana Giménez‐Capitán, Itziar de Aguirre, Cristina Queralt, José Luis Ramírez, Santiago Ramón y Cajal, Barbara Klughammer, (unknown), Walter Bordogna, David Chen, Guili Zhang, (unknown), Felice Shieh, John F. Palma, Lin Wu, H. Jeffrey Lawrence, Miquel Tarón	34
10	Biomarker Analyses from a Randomized, Placebo-Controlled, Phase IIIb Trial Comparing Bevacizumab with or without Erlotinib as Maintenance Therapy for the Treatment of Advanced Non-Small-Cell Lung Cancer (ATLAS) 2014 ·Journal of Thoracic Oncology ·Fairooz F. Kabbinavar, Louis Fehrenbacher, John D. Hainsworth, (unknown), Bruce Kressel, Thomas Marsland, Taral Patel, Mark A. Rubin, Leonard A. White, James Chih‐Hsin Yang, Barbara Klughammer, Dawn Colburn, Vincent A. Miller, Bruce E. Johnson	13
11	Quantitative Chemical Proteomics Profiling Differentiates Erlotinib from Gefitinib in EGFR Wild-Type Non–Small Cell Lung Carcinoma Cell Lines 2013 ·Molecular Cancer Therapeutics ·Angélique Augustin, Jens Lamerz, Hélène Meistermann, Sabrina Golling, Stefan Scheiblich, Johannes C. Hermann, Guillemette Duchâteau-Nguyen, Manuel Tzouros, David Ávila, Hanno Langen, Laurent Essioux, Barbara Klughammer	16
12	A phase II study of erlotinib in combination with bevacizumab versus chemotherapy plus bevacizumab in the first-line treatment of advanced non-squamous non-small cell lung cancer 2013 ·Lung Cancer ·Tudor–Eliade Ciuleanu, C.-M. Tsai, (unknown), Janusz Milanowski, D. Amoroso, (unknown), Harry J.M. Groen, Aleksandra Szczęsna, (unknown), Tsu‐Yi Chao, Gary Middleton, Ali Zeaiter, Gaëlle Klingelschmitt, Barbara Klughammer, N. Thatcher	26
13	Evaluation of EGFR protein expression by immunohistochemistry using H-score and the magnification rule: Re-analysis of the SATURN study 2013 ·Lung Cancer ·Julien Mazières, Wolfram Brugger, Federico Cappuzzo, Peter Middel, (unknown), Ilze Bāra, Gaëlle Klingelschmitt, Barbara Klughammer	78
14	Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study 2012 ·The Lancet Oncology ·Tudor–Eliade Ciuleanu, Lilia Stelmakh, Saulius Cicėnas, Skaidrius Miliauskas, Alexandru Grigorescu, Carina Hillenbach, H. Johannsdottir, Barbara Klughammer, Emilio Esteban	295
15	Tissue sampling in lung cancer: A review in light of the MERIT experience 2011 ·Lung Cancer ·Martin Reck, Andreas Hermes, Eng-Huat Tan, Enriqueta Felip, Barbara Klughammer, José Baselga	28
16	Clinical outcomes in non‐small‐cell lung cancer patients with EGFR mutations: pooled analysis 2010 ·Journal of Cellular and Molecular Medicine ·Luis Paz‐Ares, Denis Soulières, I. Melezínek, Joachim Moecks, (unknown), Tony Mok, Rafael Rosell, Barbara Klughammer	112
17	D2-04: MERIT: a prospective study of putative relationships between tumour biomarkers and clinical benefit from erlotinib in advanced non-small cell lung cancer (NSCLC) 2007 ·Journal of Thoracic Oncology ·Eng-Huat Tan, Rodryg Ramlau, A Płużańska, Han‐Pin Kuo, Barbara Klughammer, Mark Kockx, (unknown), Verena Lutz, Laurent Essioux, José Baselga	5
18	Random Insertional Mutagenesis Used in the Generation of Mutants of the Marine Cyanobacterium Synechococcus sp. Strain PCC7002 With an Impaired CO2 Concentrating Mechanism 1997 ·Australian Journal of Plant Physiology ·Dieter Sültemeyer, Barbara Klughammer, Martha Ludwig, Murray R. Badger, G. Dean Price	21
19	Partial purification of a potassium channel with low permeability for sodium from tonoplast membranes of Hordeum vulgare cv. Gerbel 1992 ·The Journal of Membrane Biology ·Barbara Klughammer, (unknown), Roland Benz, Karl‐Josef Dietz	5
20	Reconstitution of vacuolar ion channels into planar lipid bilayers 1992 ·Biochimica et Biophysica Acta (BBA) - Biomembranes ·Barbara Klughammer, Roland Benz, (unknown), (unknown), Karl‐Josef Dietz	12

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact